We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
-$260M
Cap. Flow
-$71.1M
Cap. Flow %
-2.5%
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
26
Closed
10

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$12.2M
2
SYK icon
Stryker
SYK
+$10.9M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.83M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.51M
5
BDX icon
Becton Dickinson
BDX
+$8.08M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$36.7M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.4M
3
MRK icon
Merck
MRK
+$16.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.4M
5
DHR icon
Danaher
DHR
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
2 Real Estate 3.21%
3 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$383B
$168M 5.91%
330,026
+9,672
+3% +$4.66M
AMGN icon
2
Amgen
AMGN
$209B
$139M 4.88%
574,918
– –
REGN icon
3
Regeneron Pharmaceuticals
REGN
$77.4B
$102M 3.59%
146,200
+3,151
+2% +$1.99M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$101M 3.55%
959,439
+61,899
+7% +$6.03M
GILD icon
5
Gilead Sciences
GILD
$163B
$100M 3.52%
1,686,565
– –
JNJ icon
6
Johnson & Johnson
JNJ
$617B
$91.6M 3.22%
516,652
– –
ABBV icon
7
AbbVie
ABBV
$455B
$88.9M 3.12%
548,144
+38,327
+8% +$5.57M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$122B
$80.6M 2.83%
308,884
+35,838
+13% +$8.51M
ILMN icon
9
Illumina
ILMN
$31B
$79M 2.78%
232,546
– –
ABT icon
10
Abbott
ABT
$183B
$73.2M 2.57%
618,777
+35,500
+6% +$4.4M
AZN icon
11
AstraZeneca
AZN
$266B
$65.7M 2.31%
495,338
+101,595
+26% +$12.2M
MCK icon
12
McKesson
MCK
$101B
$63.1M 2.22%
206,022
+17,500
+9% +$4.76M
PFE icon
13
Pfizer
PFE
$142B
$60.7M 2.13%
1,171,903
– –
LLY icon
14
Eli Lilly
LLY
$1.03T
$60.7M 2.13%
211,832
-18,600
-8% -$4.79M
SYK icon
15
Stryker
SYK
$133B
$60.3M 2.12%
225,678
+42,096
+23% +$10.9M
TMO icon
16
Thermo Fisher Scientific
TMO
$214B
$57.6M 2.02%
97,605
-54,721
-36% -$31.4M
MRNA icon
17
Moderna
MRNA
$23B
$56.6M 1.99%
328,524
-218,100
-40% -$36.7M
BMY icon
18
Bristol-Myers Squibb
BMY
$132B
$52.9M 1.86%
723,876
-23,167
-3% -$1.56M
MDT icon
19
Medtronic
MDT
$110B
$48.3M 1.7%
435,140
-70,720
-14% -$7.47M
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$47.6M 1.67%
330,561
-68,966
-17% -$9.33M
MRK icon
21
Merck
MRK
$321B
$47.2M 1.66%
575,622
-212,500
-27% -$16.8M
DHR icon
22
Danaher
DHR
$138B
$44M 1.55%
169,364
-58,898
-26% -$14.7M
CI icon
23
Cigna
CI
$76.1B
$41.2M 1.45%
172,023
+28,600
+20% +$6.7M
IDXX icon
24
Idexx Laboratories
IDXX
$44.1B
$33.5M 1.18%
61,217
-18,446
-23% -$9.7M
MOH icon
25
Molina Healthcare
MOH
$10.2B
$31.5M 1.11%
94,525
-3,800
-4% -$1.17M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Tekla Capital Management held 185 positions worth $2.85B, down 8.4% from $3.11B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tekla Capital Management's Q1 2022 filing shows 14 new, 26 increased, 26 reduced and 10 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M. The largest sale was Moderna, an estimated $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M.
  • Tekla Capital Management added most to AstraZeneca in Q1 2022, an estimated $12.2M increase.
  • Tekla Capital Management's biggest Q1 2022 reduction was Moderna, cutting an estimated $36.7M.
  • Tekla Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $16.4M.
  • Tekla Capital Management's ten largest holdings make up 36% of its $2.85B portfolio in Q1 2022.
  • Tekla Capital Management opened 14 new positions and closed 10 in Q1 2022.
  • Tekla Capital Management's portfolio value fell 8.4% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.